Latent tuberculosis infection: Old problem, new priorities

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 6, 2002, Pages 759-761

  Schwartzman, Kevin ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; INFLIXIMAB; ISONIAZID; LIVER ENZYME; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ASSAY; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER TOXICITY; NOTE; RISK ASSESSMENT; RISK FACTOR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS REACTIVATION;

EID: 0036207631     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (22)

1. Tuberculosis in New York City - Turning the tide
2. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997
3. A controlled trial of isoniazid prophylaxis in mental institutions
4. Targeted tuberculin testing and treatment of latent tuberculosis infection
5. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
6. Risk factors for tuberculosis in HIV-infected persons: A prospective cohort study
7. Tuberculosis in a cohort of Southeast Asian refugees
8. Epidemiological basis of tuberculosis eradication: Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area
9. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993
10. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent
11. Tuberculosis screening of immigrants to low-prevalence countries: A cost effectiveness analysis
12. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations
13. Interpretation of repeated tuberculin tests: Boosting, conversion and reversion
14. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial
15. Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy
16. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
17. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong
18. Rifampin preventative therapy for tuberculosis infection: Experience with 157 adolescents
19. An international, randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons
20. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001
21. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic